{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-038742","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.417288+00:00","generated_at":"2026-06-12T04:43:19.696028+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tango doses first patients in TNG462, TNG260 trials; CSO Alan Huang to depart; Q2 net loss narrows","bullets":["First patient dosed in phase 1/2 of TNG462 (next-gen PRMT5 inhibitor) for MTAP-deleted tumors.","First patient dosed in phase 1/2 of TNG260 (CoREST inhibitor) with pembrolizumab for STK11-mutant cancers.","CSO Alan Huang to step down Oct 2023; Jannik Andersen promoted to CSO effective Oct 9, 2023.","Cash $310.7M as of June 30, 2023, sufficient to fund operations into 2026.","Q2 2023 net loss $20.7M ($0.23/sh) vs $24.9M ($0.28/sh) in Q2 2022; license revenue $5.0M from Gilead."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-038742","json":"https://secwatch.observer/filing/0000950170-23-038742.json","markdown":"https://secwatch.observer/filing/0000950170-23-038742.md","text":"https://secwatch.observer/filing/0000950170-23-038742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/0000950170-23-038742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:43:19.696028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f0cfde04697702dee768c27a9b03534d9294b1d","claim":"Tango Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/0000950170-23-038742-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ec94b92812","claim":"Alan Huang changed role as Chief Scientific Officer at Tango Therapeutics, Inc..","evidence_excerpt":"On August 3, 2023, Alan Huang, Ph.D., the Company's Chief Scientific Officer, notified the Company that he intends to transition out of his role as Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/0000950170-23-038742-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transition out"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}